Arbutus Biopharma Corp — Director's Dealing 2021

Jun 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arbutus Biopharma Corp (ABUS)
CIK: 0001447028
Period of Report: 2021-06-03

Reporting Person: Cheng Andrew (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-03	Stock Options	$2.95	A	22000	Acquired	2031-06-03	Common Stock (22000.0)	Direct

Footnotes

F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant.

F2: The options are fully vested and exercisable as of the date of the grant.